Angelina Labib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angelina Labib has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gil Yosipovitch
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center University of Miami Miller School of Medicine Miami Florida USA
2 shared publications - Keyvan Nouri
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami Florida USA
2 shared publications - Teresa Ju
Dr Phillip Frost Department of Dermatology and Miami Itch Center University of Miami Miami FL USA
2 shared publications Ali Rajabi‐Estarabadi
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami Florida USA
1 shared publicationAllison M. Han
Rady Children's Hospital Division of Pediatric and Adolescent Dermatology San Diego USA
1 shared publicationAshley Vander Does
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center University of Miami Miller School of Medicine Miami Florida USA
1 shared publication
Latest Publications
- 19 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 121-124
Cutaneous Juvenile Xanthogranuloma With MRC1::PDGFRB Gene Fusion: A Case Report
Juvenile xanthogranulomas (JXGs) are benign solitary or multiple lesions that present as yellow‐red nodules on the skin or other organs, with histology demonstrating normolipidemic, non‐Langerhans cell histiocytosis. We present a case of a clinically atypical lesion shown to be of the JXG family of lesions following pathologic review. Next‐generation sequencing (NGS) analysis revealed a MRC1::PDGFRB gene fusion. This is the third report of the MRC1::PDGFRB gene fusion identified in JXG, and the first case of an isolated cutaneous lesion, which highlights the spectrum of the MRC1::PDGFRB gene fusion in JXG.
- 19 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 121-124
Cutaneous Juvenile Xanthogranuloma With MRC1::PDGFRB Gene Fusion: A Case Report
Juvenile xanthogranulomas (JXGs) are benign solitary or multiple lesions that present as yellow‐red nodules on the skin or other organs, with histology demonstrating normolipidemic, non‐Langerhans cell histiocytosis. We present a case of a clinically atypical lesion shown to be of the JXG family of lesions following pathologic review. Next‐generation sequencing (NGS) analysis revealed a MRC1::PDGFRB gene fusion. This is the third report of the MRC1::PDGFRB gene fusion identified in JXG, and the first case of an isolated cutaneous lesion, which highlights the spectrum of the MRC1::PDGFRB gene fusion in JXG.
- 1 March 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (7) , E818-E820
COVID‐19‐associated chilblain pruritus is non‐histaminergic mediated and correlated to epidermal interleukin 31
- 1 March 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (7) , E818-E820
COVID‐19‐associated chilblain pruritus is non‐histaminergic mediated and correlated to epidermal interleukin 31
- 8 February 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (6) , e763-e764
Patient satisfaction and quality of life in Mohs micrographic surgery: A randomized controlled clinical trial
- 8 February 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (6) , e763-e764
Patient satisfaction and quality of life in Mohs micrographic surgery: A randomized controlled clinical trial
- 26 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , 231-242
Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation
Skin carcinomas are the most common form of cancer, and every year thousands of people die from skin cancer‐related malignancies. Chronic inflammation is linked to the development and progression of cancer in multiple organ systems – about 20% of all human cancers are a result of chronic inflammation – skin included. While acute inflammation under normal circumstances is a mechanism for host defence and tissue regeneration following insult by trauma or infection by pathogens, over the long term it can drive oncogenic transformation of epithelial cells and promote cancer development, growth and metastasis. Therefore, inflammatory conditions may put individuals at a higher risk to developing skin malignancies. Many skin conditions are characterized by chronic inflammatory processes. These conditions may be particularly susceptible to malignant transformation and predispose patients to develop skin malignancies. As more pathophysiology of chronic inflammatory skin conditions is unveiled, we find that many of these conditions are characterized by immune dysregulation and signalling that result in chronic activation and upregulation of pro‐inflammatory chemokines and cytokines, leading to downstream processes that further exacerbate inflammatory processes and cause abnormal cell growth and apoptosis. Here, we review the major chronic cutaneous inflammatory diseases that may have an increased risk of skin malignancies, including atopic dermatitis, psoriasis, discoid lupus erythematosus, lichen planus, hidradenitis suppurativa, prurigo nodularis, lichen sclerosus, systemic sclerosis and morphea, chronic leg ulcers, seborrheic keratoses and basal cell carcinoma. We evaluate the evidence for increased incidence and prevalence, the risk factors associated, the populations at heightened risk and the best management practices.
- 26 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , 231-242
Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation
Skin carcinomas are the most common form of cancer, and every year thousands of people die from skin cancer‐related malignancies. Chronic inflammation is linked to the development and progression of cancer in multiple organ systems – about 20% of all human cancers are a result of chronic inflammation – skin included. While acute inflammation under normal circumstances is a mechanism for host defence and tissue regeneration following insult by trauma or infection by pathogens, over the long term it can drive oncogenic transformation of epithelial cells and promote cancer development, growth and metastasis. Therefore, inflammatory conditions may put individuals at a higher risk to developing skin malignancies. Many skin conditions are characterized by chronic inflammatory processes. These conditions may be particularly susceptible to malignant transformation and predispose patients to develop skin malignancies. As more pathophysiology of chronic inflammatory skin conditions is unveiled, we find that many of these conditions are characterized by immune dysregulation and signalling that result in chronic activation and upregulation of pro‐inflammatory chemokines and cytokines, leading to downstream processes that further exacerbate inflammatory processes and cause abnormal cell growth and apoptosis. Here, we review the major chronic cutaneous inflammatory diseases that may have an increased risk of skin malignancies, including atopic dermatitis, psoriasis, discoid lupus erythematosus, lichen planus, hidradenitis suppurativa, prurigo nodularis, lichen sclerosus, systemic sclerosis and morphea, chronic leg ulcers, seborrheic keratoses and basal cell carcinoma. We evaluate the evidence for increased incidence and prevalence, the risk factors associated, the populations at heightened risk and the best management practices.
- 20 October 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (1) , 44-49
The effect of fatty acids, vitamins, and minerals on pediatric atopic dermatitis: A systematic review
Background: A body of research has examined the role of fatty acid (FA), vitamin, and mineral supplementation as adjunctive treatment for atopic dermatitis (AD); however, results are conflicting and concrete recommendations are lacking. The objective of this study is to highlight the role of these nutrients in alleviating AD severity and provide the clinician with consolidated information that can be used to make recommendations to the pediatric patient and caretaker, where this topic is of high interest.Methods: A review of the PubMed and Embase databases was conducted to identify and qualitatively analyze all randomized controlled trials, systematic reviews, and meta‐analyses conducted within the last 21 years regarding use of these nutrients to alleviate symptoms of AD. Inclusion criteria include AD diagnosis, non‐infant age groups, and AD severity outcomes; exclusion criteria include preventative studies, predominantly maternal or infant demographics, or nonclinical outcomes.Results: Sixty‐nine studies were included. Evidence regarding FA supplementation is inconclusive; however, targeting an ideal omega‐3:omega‐6 FA ratio may play a small role in alleviating AD symptoms. Studies results regarding vitamin/mineral supplementation are inconsistent and supplementation should not be advised unless the patient has a documented deficiency.Conclusion: Pediatric AD patients should lead a healthy lifestyle with an emphasis on consumption of wholesome foods. Nutritional supplementation can play a role in improving AD symptoms; however, this should be evaluated on a case‐by‐case basis. Limitations include heterogeneity of studies.
- 20 October 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (1) , 44-49
The effect of fatty acids, vitamins, and minerals on pediatric atopic dermatitis: A systematic review
Background: A body of research has examined the role of fatty acid (FA), vitamin, and mineral supplementation as adjunctive treatment for atopic dermatitis (AD); however, results are conflicting and concrete recommendations are lacking. The objective of this study is to highlight the role of these nutrients in alleviating AD severity and provide the clinician with consolidated information that can be used to make recommendations to the pediatric patient and caretaker, where this topic is of high interest.Methods: A review of the PubMed and Embase databases was conducted to identify and qualitatively analyze all randomized controlled trials, systematic reviews, and meta‐analyses conducted within the last 21 years regarding use of these nutrients to alleviate symptoms of AD. Inclusion criteria include AD diagnosis, non‐infant age groups, and AD severity outcomes; exclusion criteria include preventative studies, predominantly maternal or infant demographics, or nonclinical outcomes.Results: Sixty‐nine studies were included. Evidence regarding FA supplementation is inconclusive; however, targeting an ideal omega‐3:omega‐6 FA ratio may play a small role in alleviating AD symptoms. Studies results regarding vitamin/mineral supplementation are inconsistent and supplementation should not be advised unless the patient has a documented deficiency.Conclusion: Pediatric AD patients should lead a healthy lifestyle with an emphasis on consumption of wholesome foods. Nutritional supplementation can play a role in improving AD symptoms; however, this should be evaluated on a case‐by‐case basis. Limitations include heterogeneity of studies.
- Open Access
- 9 June 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00729
Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch
Is missing (Short communication)
- 9 June 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00729
Open AccessEvaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch
Is missing (Short communication)